Clinical Research Directory
Browse clinical research sites, groups, and studies.
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
Sponsor: University of California, San Francisco
Summary
Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2024-05-20
Completion Date
2026-10-20
Last Updated
2025-07-08
Healthy Volunteers
No
Conditions
Interventions
Perampanel
Perampanel is a non-competitive AMPA glutamate receptor antagonist.
Placebo
Placebo
Locations (1)
Zuckerberg San Francisco General Hospital
San Francisco, California, United States